XORTX Therapeutics Inc. stock is up 0.86% since 30 days ago. The next earnings date is Apr 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 38.46% of the previous 19 February’s closed higher than January.
XORTX Therapeutics Inc. develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!